About GSK

We are a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer. We have three global businesses that research, develop and manufacture innovative pharmaceutical medicines, vaccines and consumer healthcare products.

Everyone at GSK focuses on three priorities: Innovation, Performance, Trust

Dave Kilian, Oncology scientist sitting at a lab table
Dave Kilian, Oncology scientist, USA

Innovation

We invest in scientific and technical excellence to develop and launch a pipeline of new products that meet the needs of patients, payers and consumers.

  • £3.9bn

    R&D investment in 2017

  • 3

    significant approvals in 2017 – Shingrix, Trelegy Ellipta and Juluca

  • £6.7bn

    new product sales in Pharmaceuticals and Vaccines in 2017

  • 13%

    13% Consumer Healthcare sales in 2017 from product innovations launched over the past three years

Dawn, pharmacist with pharmacy products on shelves in our Shopper Science Lab
Dawn Skelton, Pharmacist, UK

Performance

We aim to achieve industry-leading growth by investing effectively in our business, developing our people and delivering flawlessly.

  • £30.2bn

    total turnover in 2017

  • £8.6bn

    adjusted operating profit in 2017

  • £3.4bn

    free cash flow in 2017

  • £3.9bn

    dividends paid in 2017

Mother holding her baby, Ghana

Trust

We commit to ensuring the quality, safety and reliable supply of our products; and to building trust through our approach to engagement, pricing, global health and being a modern employer.

  • 85%

    of employees proud to work at GSK

  • £261.6m

    donated in 2017 to local communities through product donations, time and cash

  • 1st

    in Access to Medicines Index all 5 times since its launch in 2008

Read more

Our three global businesses

Pharmaceuticals

Our Pharmaceutical business has a broad portfolio of innovative and established medicines. We currently focus on developing new medicines in respiratory and HIV/infectious diseases, oncology and immuno-inflammation; with discovery research exploring these and other areas.

 

Image: Illustration of t-cells engaging and destroying the cancer cellImmune system T-cells attacking a cancer cell
Meningococcal serogroup B bacteria, commonly known as meningitis B, new

Vaccines

Our Vaccines business has a broad portfolio and innovative pipeline of vaccines to protect people of all ages. We deliver over two million vaccine doses per day to people living in over 160 countries.

 

Image: Meningococcal serogroup B bacteria, commonly known as meningitis B
NovaMin 2

Consumer Healthcare

Our Consumer Healthcare business develops and markets consumer preferred and expert recommended brands in the Oral health, Pain relief, Respiratory, Nutrition/gastro-intestinal and Skin health categories.

 

Image: Novamin, which helps to repair and protect sensitive teeth

Find out more about us